DrugPatentWatch Database Preview

Details for Patent: 8,618,141

« Back to Dashboard

Which drugs does patent 8,618,141 protect, and when does it expire?

Patent 8,618,141 protects NEXAVAR and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 8,618,141

Title:	Aryl ureas with angiogenesis inhibiting activity
Abstract:	This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Inventor(s):	Dumas; Jacques (Bethany, CT), Scott; William J. (Guilford, CT), Elting; James (Madison, CT), Hatoum-Makdad; Holia (Hamden, CT)
Assignee:	Bayer Healthcare LLC (Whippany, NJ)
Application Number:	13/551,884
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,618,141
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 8,618,141

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005		RX	Yes	Yes						TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Non-Orange Book US Patents Family Members for Patent 8,618,141

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,838,541	Aryl ureas with angiogenesis inhibiting activity
8,242,147	Aryl ureas with angiogenisis inhibiting activity

International Family Members for US Patent 8,618,141

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2475703
Denmark	1478358
European Patent Office	1478358
European Patent Office	2324825